- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00997607
Evaluating an Ebola and a Marburg Vaccine in Uganda
A Phase IB Study to Evaluate the Safety and Immunogenicity of an Ebola DNA Plasmid Vaccine, VRC-EBODNA023-00-VP, and a Marburg DNA Plasmid Vaccine, VRC-MARDNA025-00-VP, in Healthy Adults in Kampala, Uganda
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Ebola and Marburg viruses are both filoviruses known to induce hemorrhagic fever-a set of symptoms characterized by sudden onset, aching, fever, and bleeding in the internal organs. Both filoviruses are associated with high mortality rates, and the Centers for Disease Control (CDC) lists them as Category A bioterrorism agents because of their potential for a major public health impact. Vaccines for both viruses are under development using a prime-boost strategy that involves multiple injections over a period of time to confer long-lasting immunity. Preliminary research supports the vaccines' safety. This study will test these experimental vaccines for the Ebola and Marburg viruses, first administered separately and then together, to ensure they are safe and do not have side effects.
Participation in this study will entail 11 study visits over 2 years. The study will have two parts, to be completed sequentially, and three groups. In part one, participants will be randomly assigned to the first group, which will receive the experimental Ebola DNA vaccine, or the second group, which will receive the experimental Marburg DNA vaccine. In part two, the third group will receive both the Ebola and the Marburg vaccines, one shot in each arm. One fifth of the participants in each group will be controls and receive placebo injections. All vaccines and placebos will be delivered via an intramuscular injection at three time points: at study entry, after 4 weeks, and after 8 weeks.
Participants will complete study assessments at 12 points in time: at baseline and at Weeks 2, 4, 6, 8, 10, 12, 24, 32, 52, 78, and 104. At each assessment, changes in health and medications will be recorded and blood will be drawn. Participants will also complete a diary card daily for 5 days after receiving each injection. In it, they will record their temperature and any skin changes at the injection site.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Kampala, Uganda
- Makerere University Walter Reed Project (MUWRP) clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Available for clinical follow-up through Week 104
- Willing to have photo taken for identification purposes
- Willing to be taken home at enrollment visit and allow home visits if appointments are not kept
- Completes an Assessment of Understanding (AoU) prior to enrollment by answering 9 out of 10 questions at least once in 3 attempts
- In good general health without clinically significant medical history
- Has a physical examination and laboratory results without clinically significant findings within the 28 days prior to enrollment
- Female participants of reproductive potential must have a negative result on a human choriogonadotropin (β-HCG) pregnancy test
- Female participants must either be incapable of becoming pregnant or agree to take appropriate precautions that pregnancy will not occur during the first 24 weeks of the study
Exclusion Criteria:
- Pregnant, breast-feeding, or planning to become pregnant during the first 24 weeks after enrollment
- History of Ebola or Marburg virus exposure
- Occupational health risk of exposure to the Ebola or Marburg virus known to be higher than that of the general population
Has received any of the following substances:
- Investigational Ebola or Marburg vaccine in a prior clinical trial
- Blood products within 120 days prior to HIV screening
- Immunoglobulin within 60 days of prior to HIV screening
- Live attenuated vaccines within 30 days prior to initial study vaccine administration
- Investigational research agents within 30 days prior to initial study vaccine administration
- Medically indicated subunit or killed vaccines (such as influenza, pneumococcal, or allergy treatment with antigen injections) within 14 days of study vaccine administration
- Current anti-tuberculosis prophylaxis or therapy
- Immunosuppressive medications, cytotoxic medications, inhaled corticosteroids, or long-acting beta-agonists within 12 weeks of enrollment, except in the following cases: use of corticosteroid nasal spray for rhinitis, topical corticosteroids for an acute uncomplicated dermatitis; or a short course (duration of 10 days or less, or a single injection) of corticosteroids for a non-chronic condition (based on investigator clinical judgement) at least 2 weeks prior to enrollment in this study
- History of serious adverse reactions to vaccines such as anaphylaxis, urticaria (hives), respiratory difficulty, angioedema, or abdominal pain
- Presence of idiopathic urticaria within the past 2 years
- History of autoimmune disease or immunodeficiency
- History of unstable asthma; asthma that required emergent care, urgent care, hospitalization or intubation during the past 2 years; or asthma that requires the use of oral or parenteral corticosteroids
- History of diabetes mellitus (type I or II), with the exception of a history of gestational diabetes
- History of thyroidectomy or thyroid disease that required medication within the past 12 months
- History of hereditary angioedema (HAE), acquired angioedema (AAE), or idiopathic forms of angioedema
- History of hypertension that is not well controlled by medication or blood pressure that is more than 145/95 mm Hg at enrollment
- Presence of a bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions), significant bruising or bleeding difficulties with intramuscular injections or blood draws, or routine use of anticoagulant medications
- Presence of active malignancy, treated malignancy for which there is not reasonable assurance of sustained cure, or malignancy that is likely to recur during the period of the study
- History of a seizure or seizure disorder
- Asplenia, functional asplenia, or any condition resulting in the absence or removal of the spleen
- Allergic reaction to aminoglycoside antibiotics
- Presence of a psychiatric condition that precludes compliance with the protocol
- History of psychoses, bipolar disorder, disorder requiring lithium, or suicide plan or attempt within 5 years prior to enrollment
- Any medical, psychiatric, social condition, occupational reason, or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject's ability to give informed consent
- Evidence of syphilis based on history, exam, and rapid plasma reagin (RPR) test results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Ebola vaccine only
Participants will receive only the Ebola vaccine or a placebo injection.
|
4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
4 mg of saline injection delivered at Weeks 0, 4, and 8
|
EXPERIMENTAL: Marburg vaccine only
Participants will receive only the Marburg vaccine or a placebo injection.
|
4 mg of saline injection delivered at Weeks 0, 4, and 8
4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
|
EXPERIMENTAL: Ebola and Marburg vaccine
Participants will receive both the Ebola and Marburg vaccines, one in each arm or placebo injections.
|
4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
4 mg of saline injection delivered at Weeks 0, 4, and 8
4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety of Ebola vaccine, as seen in local and systemic reactogenicity signs and symptoms, laboratory measures of safety, and adverse and serious adverse experiences
Time Frame: Measured at 11 or more visits over 2 years
|
Measured at 11 or more visits over 2 years
|
Safety of Marburg vaccine, as seen in local and systemic reactogenicity signs and symptoms, laboratory measures of safety, and adverse and serious adverse experiences
Time Frame: Measured at 11 or more visits over 2 years
|
Measured at 11 or more visits over 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Immunogenicity of Ebola vaccine, as seen in ELISA antigen-specific assays for antibodies, intracellular cytokine staining (ICS) assay, and an ELISPOT antigen-specific assay for T cell responses
Time Frame: Measured at baseline and Week 12
|
Measured at baseline and Week 12
|
Immunogenicity of Marburg vaccine, as seen in ELISA antigen-specific assays for antibodies, intracellular cytokine staining (ICS) assay, and an ELISPOT antigen-specific assay for T cell responses
Time Frame: Measured at baseline and Week 12
|
Measured at baseline and Week 12
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hannah Kibuuka, MBChB, MMed, MPH, Makerere University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RV 247
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ebola Virus Disease
-
National Institute of Allergy and Infectious Diseases...CompletedEbola Virus Disease | Ebola Hemorrhagic Fever | Ebola Virus Vaccines | Envelope Glycoprotein, Ebola Virus | FilovirusUnited States
-
Jiangsu Province Centers for Disease Control and...Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology IncCompletedEbola DiseaseSierra Leone
-
Cerus CorporationTerminated
-
National Institute of Allergy and Infectious Diseases...CompletedEbola VirusUnited States, Congo, The Democratic Republic of the
-
National Institute of Allergy and Infectious Diseases...CompletedEbola Virus Disease | Ebola Vaccines | Marburg Virus Disease | Marburgvirus | EbolavirusUnited States
-
London School of Hygiene and Tropical MedicineCompletedHiv | Ebola Virus Disease | EbolaKenya, Uganda
-
Janssen Vaccines & Prevention B.V.Institut National de la Santé Et de la Recherche Médicale, France; University...CompletedEbola Viral DiseaseFrance, United Kingdom
-
MRC/UVRI and LSHTM Uganda Research UnitMinistry of Health, UgandaRecruiting
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University... and other collaboratorsNot yet recruiting
Clinical Trials on Ebola vaccine
-
Auro Vaccines LLCUnited States Department of Defense; AccelovanceCompletedEbola Virus DiseaseUnited States
-
Jiangsu Province Centers for Disease Control and...Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology IncCompletedEbola DiseaseSierra Leone
-
National Institute of Allergy and Infectious Diseases...CompletedEbola Disease | Marburg DiseaseUnited States
-
University of OxfordUniversity of GlasgowCompletedEbola Virus DiseaseUnited Kingdom
-
Cecile TremblayMerck Sharp & Dohme LLC; Dalhousie University; Université de Montréal; Coalition... and other collaboratorsActive, not recruiting
-
Jiangsu Province Centers for Disease Control and...Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology IncCompleted
-
Jiangsu Province Centers for Disease Control and...Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology IncCompletedEbola Virus DiseaseChina
-
National Institute of Allergy and Infectious Diseases...CompletedEbola Disease | ImmunisationUnited States
-
Emory UniversityWashington University School of Medicine; Merck Sharp & Dohme LLCNot yet recruiting
-
Tulane UniversityMerck Sharp & Dohme LLC; Kenema Government HospitalNot yet recruiting